Using Tenecteplase to treat Central Retinal Artery Occlusion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Tenecteplase, a thrombolytic agent, in treating patients with Central Retinal Artery Occlusion (CRAO) when administered within 4.5 hours of symptom onset. It is a phase 3, randomized, double-blind, and multi-center trial comparing Tenecteplase to Acetylsalicylic Acid (ASA) in a 1:1 ratio. Patients will be monitored in stroke units and assessed for visual acuity improvements at 30 and 90 days post-treatment. The study aims to provide evidence on whether early systemic thrombolysis can enhance visual outcomes in CRAO patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Non-arteritic central retinal artery occlusion with ≥ 1.0 logMAR visual acuitiy and symptoms lasting less than 4.5 hours.
2. Ability to administer the Investigator Medicinal Product (IMP) within 4.5 hours of symptom onset.
3. Age ≥18 years.
4. Informed written consent of the patient.
5. A woman of childbearing potential (WOCBP) must confirm that in her opinion, she cannot be pregnant, OR if there is a possibility that she is pregnant, a negative pregnancy test must be confirmed before any IMP is given.

Exclusion Criteria:

1. No other active intervention targeting CRAO.
2. Branch retinal artery occlusion, cilioretinal artery supplying the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy, elevated intraocular pressure (\> 30 mmHg) or clinical suspicion of ophthalmic artery occlusion occlusion (e.g. choroidal nonperfusion, absence of cherry red spot, no light perception).
3. Systemic diseases; severe general diseases, systemic arterial hypertension (blood pressure \>185/110 mmHg), despite medical therapy, or clinical suspicion of acute systemic inflammation.
4. Presence of intracranial haemorrhage on brain MRI/CT.
5. Medical history: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation within the last 4 weeks, therapy with anticoagulation, allergic reaction to contrast agent, hemorrhagic diathesis, aneurysms, inflammatory vascular diseases (eg, giant cell arteritis, granulomatosis with polyangitis), endocarditis, or gastric ulcer.
6. No willingness and ability of the patient to participate in all follow-up examinations.
7. Pregnancy (if suspicion of pregnancy s-hCG or u-hCG must be negative).
8. Allergy or intolerance to any ingredients of IMP or placebo or gentamicin.
9. Other conditions / circumstances likely to lead to poor treatment adherence (eg, history of poor compliance, alcohol or drug dependency, no fixed abode).
10. Significant bleeding disorder either at present or within the past 6 months.
11. Effective oral anticoagulant treatment, eg, warfarin sodium (INR \>1.3).
12. Effective anticoagulant treatment with heparin or low molecular weight heparin the last 48 hours.
13. Any history of central nervous system damage (ie, neoplasm, aneurysm, intracranial or spinal surgery).
14. Known hemorrhagic diathesis.
15. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with acute myocardial infarction).
16. Recent non-compressible vessel puncture within 2 weeks.
17. Recent trauma to the head or cranium.
18. Prolonged cardiopulmonary resuscitation (\>2 minutes) within the past 2 weeks.
19. Acute pericarditis and/or subacute bacterial endocarditis.
20. Acute pancreatitis.
21. Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis.
22. Active peptic ulceration.
23. Arterial aneurysm and known arterial/venous malformation.
24. Neoplasm with increased bleeding risk.
25. Any known history of hemorrhagic stroke or stroke of unknown origin.
26. Known history of ischemic stroke or transient ischemic attack in the preceding 3 months.
27. Dementia.

Where it's running

• Oslo University Hospital
  Oslo, Norway Recruiting
• St Vincent's Hospital Melbourne
  Melbourne, Australia Withdrawn
• ULB-Hôpital Erasme
  Anderlecht, Belgium Withdrawn
• University Hospital Antwerp
  Antwerp, Belgium Completed
• UZ Brussel
  Brussel, Belgium Withdrawn
• University Hospital Leuven
  Leuven, Belgium Completed

Study contacts

• Study coordinator: Anne Hege Aamodt
• Email: a.h.aamodt@medisin.uio.no
• Phone: +47 23074976

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microneedle intra-arterial injection plus vitrectomy for acute retinal artery occlusion

  This trial will try a microneedle intra-arterial thrombolytic injection combined with vitrectomy to restore vision in adults with acute central retinal artery occlusion or macula-involving branch retinal artery occlusion within 7 days of symptoms.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07151755

• Understanding how Giant Cell Arteritis affects vision

  This study is trying to understand how Giant Cell Arteritis affects vision in adults by comparing eye health in those with GCA-related vision problems to those with other causes of vision loss.

  Recruiting ASST Fatebenefratelli Sacco · Milan, Lombardy · NCT06500728

• Proton Re-irradiation for Recurrent or Second Primary Head and Neck Cancer

  This study tests proton radiotherapy to see if it can control head and neck cancer that has come back or appeared again in the same area, while trying to limit side effects.

  Recruiting Oslo University Hospital · Bergen and 3 other locations · NCT07922967

• Predicting high-risk arrhythmic events in people with arrhythmic mitral valve prolapse

  This study tests a risk model to see which patients with arrhythmic mitral valve prolapse might need an ICD.

  Recruiting Oslo University Hospital · Oslo · NCT07830888

• Digital long-term follow-up for heart disease survivors using HeartCheck

  A smartphone-based program called HeartCheck is tested to help adults who survived a recent heart attack or PCI stay on top of risk factors and medications over time.

  Recruiting at 2 sites Oslo University Hospital · Arendal and 1 other locations · NCT07720349

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.